Heska (HSKA) Tops Q4 EPS by 5c, Miss on Revenues

Note: EPS may not be comparable

Heska (NASDAQ: HSKA) reported Q4 EPS of $0.63, $0.05 better than the analyst estimate of $0.58. Revenue for the quarter came in at $36 million versus the consensus estimate of $40.99 million.

Kevin Wilson, Heska's Chief Executive Officer and President, commented, "On a non-GAAP basis adjusted for impacts from U.S. Tax Reform(1), Heska earned $0.63 per diluted share in the period, up 37.0% over the prior year period; for the full year, Heska earned $2.07 per diluted share, up 44.8% over the prior year period and in excess of our full year target. We outperformed in our key blood diagnostics lines and we exceeded our profitability targets with record gross margins, operating margins, and earnings(1). Offsetting these successes, we fell short in imaging revenues, which are again growing in early 2018. Our point of care laboratory Heska Reset subscriptions are healthy and continue to be Heska\'s core growth and margin engine with solid placements growth, increasing tests volume, excellent margins, strong renewals and extensions, and nearly universal retention. Entering 2018, our job at Heska is clear: (1) continue to win in our baseline domestic plan that emphasizes Heska Reset diagnostics subscriptions, (2) return to growth in imaging, and (3) work to deliver on our next big product and geographic expansion opportunities to drive major steps up in growth. I am optimistic that we can do these things well."

For earnings history and earnings-related data on Heska (HSKA) click here.

You May Also Be Interested In

• SanDisk upgraded at JPMorgan after investor day; shares climb
• Prosensa Holding N.V. (RNA) Reports Q2 Loss of $1.18
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c